The cost per patient for Adcetris may run up to $121,500 or even higher, to treat two rare blood cancers. Having seen Dendreon's implosion, some investors are selling.
On the other end, Canaccord Genuity analyst George Farmer views those estimates as “unrealistically high” and predicts just under $200 million in sales by 2018. He recommends selling the stock and maintains a $10 price target on the shares.
Market Data 
Markets 
AI
